TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。阿尔茨海默病（简称AD）是一种导致思考和记忆能力日益困难的疾病。思维和记忆的衰退被称为“痴呆症”，而阿尔茨海默病是美国最常见的痴呆症原因。阿尔茨海默病的确切病因尚不清楚。有证据表明，减缓或帮助预防AD的一种方法可能是降低胆固醇。该研究项目将研究一种被称为辛伐他汀的药物是否也可能有助于减轻阿尔茨海默病的症状，辛伐他汀是fda批准的一种通常用于降低胆固醇的药物。预计约有10名参与者将在该网站注册。将有400名参与者在美国大约40个研究地点参加这项研究。参加该计划的人必须年满50岁，并被诊断患有阿尔茨海默病。根据病史、医生检查和实验室检查确定的医疗状况和身体健康状况必须是可以接受的。有些人可能没有资格参加，如果他们正在使用不允许的药物，或者如果医生根据他们的一系列认知和身体测试的结果确定他们不符合资格。如果一个人怀孕或对研究药物过敏，他们不能参加。参与者将被随机分配接受辛伐他汀或安慰剂。随机的意思是偶然的，就像抛硬币一样。安慰剂是指一种无活性的物质，有时也被称为“假药丸”或“糖丸”。安慰剂预计对阿尔茨海默病没有任何效果。参与者将服用18个月的研究药物，并将来诊所8次。在诊所访问期间，他们将接受思维和记忆测试，并抽取血液样本。研究人员将测量服用辛伐他汀的人与服用安慰剂的人在思维和记忆能力方面是否有任何差异。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's disease (abbreviated AD) is an illness that causes increasing difficulty in the ability to think and remember. The decline of thinking and memory is known as "dementia," and AD is the most common cause of dementia in the U.S. The exact cause of AD is not known. There is some evidence that one way to slow down or help prevent AD may be to lower cholesterol. This research project will study whether a drug called simvastatin, which is an FDA-approved drug commonly used to lower cholesterol, might also help reduce AD symptoms. Approximately 10 participants are expected to be enrolled at this site. There will be 400 participants enrolled in this research study at approximately 40 study sites in the United States. To be enrolled, a person must be 50 years old and above and have a diagnosis of Alzheimer's disease. Medical condition and physical health must be acceptable as determined by medical history, a doctor's examination and laboratory tests. Some people may not be eligible to participate if they are using medications that are not allowed, or if the doctor determines they do not qualify based on their results from a set of cognitive and physical tests. If a person is pregnant or allergic to study medication, they must not participate. People who participate will be randomly assigned to receive simvastatin or a placebo. Randomly means by chance, like flipping a coin. Placebo means an inactive substance, sometimes called a "dummy pill" or "sugar pill." A placebo is not expected to have any effect on AD. Participants will take study medication for 18 months, and will come to the clinic 8 times. During the clinic visits, they will have tests of their thinking and memory, and blood samples will be drawn. Researchers will measure whether there is any difference in thinking and memory skills between people who were on simvastatin compared to people who were on placebo.